MX2010000236A - Variantes de empalme cd44 en enfermedades neurodegenerativas. - Google Patents
Variantes de empalme cd44 en enfermedades neurodegenerativas.Info
- Publication number
- MX2010000236A MX2010000236A MX2010000236A MX2010000236A MX2010000236A MX 2010000236 A MX2010000236 A MX 2010000236A MX 2010000236 A MX2010000236 A MX 2010000236A MX 2010000236 A MX2010000236 A MX 2010000236A MX 2010000236 A MX2010000236 A MX 2010000236A
- Authority
- MX
- Mexico
- Prior art keywords
- seq
- neurodegenerative diseases
- splice variants
- sequence
- homologous
- Prior art date
Links
- 230000004770 neurodegeneration Effects 0.000 title abstract 3
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 3
- 101150017002 CD44 gene Proteins 0.000 title 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 239000002773 nucleotide Substances 0.000 abstract 2
- 125000003729 nucleotide group Chemical group 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 229920002477 rna polymer Polymers 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70585—CD44
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Psychology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92970607P | 2007-07-10 | 2007-07-10 | |
| PCT/IB2008/052786 WO2009007934A2 (en) | 2007-07-10 | 2008-07-10 | Cd44 splice variants in neurodegenerative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010000236A true MX2010000236A (es) | 2010-06-02 |
Family
ID=40229192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010000236A MX2010000236A (es) | 2007-07-10 | 2008-07-10 | Variantes de empalme cd44 en enfermedades neurodegenerativas. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9018180B2 (OSRAM) |
| EP (1) | EP2167692B1 (OSRAM) |
| JP (1) | JP2010532989A (OSRAM) |
| KR (1) | KR20100044793A (OSRAM) |
| CN (1) | CN101821407B (OSRAM) |
| AU (1) | AU2008273713B2 (OSRAM) |
| BR (1) | BRPI0814685A2 (OSRAM) |
| CA (1) | CA2692861A1 (OSRAM) |
| EA (1) | EA201070108A1 (OSRAM) |
| ES (1) | ES2423182T3 (OSRAM) |
| IL (1) | IL203130A (OSRAM) |
| MX (1) | MX2010000236A (OSRAM) |
| NZ (1) | NZ582390A (OSRAM) |
| WO (1) | WO2009007934A2 (OSRAM) |
| ZA (1) | ZA201000083B (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101945869B (zh) | 2007-12-19 | 2014-06-18 | 癌症研究技术有限公司 | 吡啶并[2,3-b]吡嗪-8-取代化合物及其用途 |
| US8815896B2 (en) | 2010-02-01 | 2014-08-26 | The Institute Of Cancer Research: Royal Cancer Hospital | 1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-B]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy |
| BR112013024323A2 (pt) * | 2011-03-24 | 2017-06-13 | Neurim Pharmaceuticals ( 1991 ) Ltd | peptídeos neuroprotetores |
| US9399779B2 (en) * | 2011-06-08 | 2016-07-26 | The Corporation Of Mercer University | Alternative splicing constructs and methods of use |
| CN104277092B (zh) * | 2013-07-12 | 2017-10-31 | 天津医科大学 | 用于预防和/或治疗老年性痴呆的β片层阻断肽 |
| GB201320732D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Methods of chemical synthesis |
| GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| US10400009B2 (en) | 2014-09-04 | 2019-09-03 | Tianjin Medical University | β-sheet breaker peptide used for preventing and/or treating alzheimer's disease |
| CN107815438A (zh) * | 2017-08-02 | 2018-03-20 | 清华大学 | 重组细胞、筛选l型钙通道调节剂的方法、试剂在制备药物中的用途和药物组合物 |
| CN117377777A (zh) | 2021-05-11 | 2024-01-09 | 纽瑞姆制药（1991）有限公司 | 诊断和治疗具有2号染色体2:107,510,000-107,540,000基因座单核苷酸多态性受试者的方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5990299A (en) * | 1995-08-14 | 1999-11-23 | Icn Pharmaceuticals, Inc. | Control of CD44 gene expression for therapeutic use |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| US6150162A (en) | 1998-12-17 | 2000-11-21 | Isis Pharmaceuticals Inc. | Antisense modulation of CD44 expression |
| IL133647A0 (en) * | 1999-06-08 | 2001-04-30 | Yissum Res Dev Co | Novel cd44 variant |
| WO2002081628A2 (en) * | 2001-04-05 | 2002-10-17 | Ribozyme Pharmaceuticals, Incorporated | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies |
| DK2796553T3 (da) | 2000-03-30 | 2019-09-30 | Whitehead Inst Biomedical Res | Rna-sekvensspecifikke formidlere af rna-interferens |
| CZ302719B6 (cs) * | 2000-12-01 | 2011-09-21 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití |
| WO2002076510A1 (en) | 2001-03-23 | 2002-10-03 | Agy Therapeutics | Use of biomolecular targets in the treatment and visualization of brain tumors |
| WO2002097044A2 (en) | 2001-05-25 | 2002-12-05 | Thomas Jefferson University | Alternative splice forms of proteins as basis for multiple therapeutic modalities |
| US7833779B2 (en) * | 2001-07-25 | 2010-11-16 | Jivan Biologies Inc. | Methods and systems for polynucleotide detection |
| JP2007508810A (ja) * | 2003-09-30 | 2007-04-12 | エヴォテック ニューロサイエンシス ゲゼルシャフト ミット ベシュレンクテル ハフツング | スルホトランスフェラーゼの神経変性疾患に関する診断的および治療的使用 |
| JP2008546379A (ja) * | 2005-06-16 | 2008-12-25 | エボテツク・ニユーロサイエンシーズ・ゲー・エム・ベー・ハー | 神経変性疾患のための診断および治療の標的ａｄａｒｂ２タンパク質 |
-
2008
- 2008-07-10 MX MX2010000236A patent/MX2010000236A/es active IP Right Grant
- 2008-07-10 AU AU2008273713A patent/AU2008273713B2/en active Active
- 2008-07-10 US US12/668,563 patent/US9018180B2/en active Active
- 2008-07-10 ES ES08776569T patent/ES2423182T3/es active Active
- 2008-07-10 NZ NZ582390A patent/NZ582390A/en not_active IP Right Cessation
- 2008-07-10 BR BRPI0814685A patent/BRPI0814685A2/pt not_active IP Right Cessation
- 2008-07-10 EA EA201070108A patent/EA201070108A1/ru unknown
- 2008-07-10 WO PCT/IB2008/052786 patent/WO2009007934A2/en not_active Ceased
- 2008-07-10 CN CN2008801049431A patent/CN101821407B/zh active Active
- 2008-07-10 KR KR1020107001642A patent/KR20100044793A/ko not_active Ceased
- 2008-07-10 JP JP2010515648A patent/JP2010532989A/ja active Pending
- 2008-07-10 EP EP08776569.9A patent/EP2167692B1/en active Active
- 2008-07-10 CA CA 2692861 patent/CA2692861A1/en not_active Abandoned
-
2010
- 2010-01-04 IL IL203130A patent/IL203130A/en not_active IP Right Cessation
- 2010-01-05 ZA ZA2010/00083A patent/ZA201000083B/en unknown
-
2015
- 2015-03-27 US US14/671,281 patent/US9416166B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201000083B (en) | 2011-03-30 |
| CN101821407B (zh) | 2013-09-18 |
| US20150266940A1 (en) | 2015-09-24 |
| CN101821407A (zh) | 2010-09-01 |
| EP2167692A2 (en) | 2010-03-31 |
| BRPI0814685A2 (pt) | 2019-09-24 |
| US9416166B2 (en) | 2016-08-16 |
| HK1145856A1 (en) | 2011-05-06 |
| WO2009007934A3 (en) | 2009-05-07 |
| JP2010532989A (ja) | 2010-10-21 |
| EA201070108A1 (ru) | 2010-06-30 |
| NZ582390A (en) | 2012-05-25 |
| ES2423182T3 (es) | 2013-09-18 |
| CA2692861A1 (en) | 2009-01-15 |
| KR20100044793A (ko) | 2010-04-30 |
| IL203130A (en) | 2014-07-31 |
| US20110172286A1 (en) | 2011-07-14 |
| AU2008273713A1 (en) | 2009-01-15 |
| AU2008273713B2 (en) | 2014-07-03 |
| US9018180B2 (en) | 2015-04-28 |
| WO2009007934A2 (en) | 2009-01-15 |
| EP2167692B1 (en) | 2013-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2010000236A (es) | Variantes de empalme cd44 en enfermedades neurodegenerativas. | |
| ES2962434T3 (es) | Procedimientos y composiciones para editar ARN | |
| WO2003072711A3 (en) | Method of using modified oligonucleotides for hepatic delivery | |
| WO2006119266A3 (en) | Human micrornas and methods for inhibiting same | |
| WO2007117438A3 (en) | Methods for the production of functional protein from dna having a nonsense mutation and the treatment of disorders associated therewith | |
| WO2009150222A3 (en) | Improved protein expression system | |
| Ramirez et al. | Molecular characterization and evolution of a duck mitochondrial genome | |
| WO2008132234A4 (en) | Rna antagonist compounds for the modulation of beta-catenin | |
| EP2679246A3 (en) | Novel therapeutical tools and methods for treating blindness | |
| WO2007128477A3 (en) | SHORT INTERFERING RIBONUCLEIC ACID (siRNA) FOR ORAL ADMINISTRATION | |
| BR112014001909A2 (pt) | gene da toxina axmi270 e métodos para a sua utilização | |
| JP2002272489A5 (OSRAM) | ||
| BR112014002027A2 (pt) | gene pesticida axmi279 e métodos para a sua utilização | |
| NZ598351A (en) | Il-17 binding compounds and medical uses thereof | |
| MX2011006693A (es) | Genes pesticidas de brevibacillus y metodos para su uso. | |
| EA201170685A1 (ru) | Гены, кодирущие токсины нематод | |
| WO2010060967A3 (en) | Compositions and methods for treating retrovirus infections | |
| ATE528008T1 (de) | Rnai-modulation von aha und ihre therapeutische verwendung | |
| NZ604057A (en) | Plant cytochrome p450 | |
| IL201963A (en) | Vectors for multi-gene expression, host cell and pharmacy preparation containing and using them | |
| MX2009000654A (es) | Medios para inhibir la expresion de la cinasa de proteina 3. | |
| WO2010006973A3 (en) | Compositions and methods for inhibiting expression of tgf-beta receptor genes | |
| BR112014022034A2 (pt) | gene da toxina axmi335 de bacillus thuringiensis e métodos para a sua utilização | |
| BR112012010537A2 (pt) | "clonagem, expressão e uso de fosfolipases ácidas" | |
| WO2008001219A3 (en) | Cancer therapy using bcl-xl-specific sina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |